


(wileyonlinelibrary.com) DOI:10.1002/jlcr.1684

# Current awareness in labelled compounds and radiopharmaceuticals

## Current Awareness – Use the links online

### View this bibliography online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)

The articles use , the innovative multi-publisher reference linking. This enables readers to move seamlessly from the reference to the cited publication, typically located on a different server and published by a different publisher. Links to MEDLINE abstracts are also available for key journals in the biosciences.

06810

## 1 Radionuclide production

Khandaker MU, Kim K, Kim G\*, Otuka N// \*Kyungpook Natl Univ, Sch Phys & Energy Sci, 1370 Sankyok dong, Buk gu, Taegu 702 701, South Korea

*Nucl Instrum Methods Phys Res B* 2010 **268** (14) 2303-2311  
Cyclotron production of the  $^{105,106m}\text{Ag}$ ,  $^{100,101}\text{Pd}$ ,  $^{100,101m,105}\text{Rh}$  radionuclides by  $^{nat}\text{Pd}(\text{p},\text{x})$  nuclear processes

Kim JH, Park H, Chun KS\*// \*Korea Inst Radiol & Med Sci - KIRAMS, Lab Radiopharmaceut, 215-4 Gongreung dong, Nowon gu, Seoul 139 706, South Korea

*Appl Radiat Isot* 2010 **68** (9) 1623-1626  
Effective separation method of  $^{64}\text{Cu}$  from  $^{67}\text{Ga}$  waste product with a solvent extraction and chromatography

Pruszyński M, Loktionova NS, Filosofov DV, Rosch F\*// \*Johannes Gutenberg University Mainz, Institute Nucl Chem, DE-55128 Mainz, Germany

*Appl Radiat Isot* 2010 **68** (9) 1636-1641  
Post-elution processing of  $^{44}\text{Ti}/^{44}\text{Sc}$  generator-derived  $^{44}\text{Sc}$  for clinical application

Saiki H, Iwata R\*, Nakanishi H, Wong R, Ishikawa Y, Furumoto S, Yamahara R, Sakamoto K, Ozeki E// \*Tohoku Univ, Ctr Cyclotron & Radioisotope, Sendai, Miyagi 980 8578, Japan

*Appl Radiat Isot* 2010 **68** (9) 1703-1708  
Electrochemical concentration of no-carrier-added  $^{18}\text{F}$  fluoride from  $^{18}\text{O}$  water in a disposable microfluidic cell for radiosynthesis of  $^{18}\text{F}$ -labeled radiopharmaceuticals

## 2 Labelled compound synthesis

Ahlgren S, Andersson K, Tolmachev V// Uppsala Univ, Dept Med Sci, Div Nucl Sci, SE-75185 Uppsala, Sweden

*Nucl Med Biol* 2010 **37** (5) 539-546  
Kit formulation for  $^{99m}\text{Tc}$ -labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine

Akurathi V, Dubois L, Lieuwes NG, Chitneni SK, Cleynhens BJ, Vullo D, Supuran CT, Verbruggen AM, Lambin P, Bormans GM\*// \*Post Box 821, O&N2, Herestr 49, BE-3000 Louvain, Belgium

*Nucl Med Biol* 2010 **37** (5) 557-564  
Synthesis and biological evaluation of a  $^{99m}\text{Tc}$ -labelled sulfonamide conjugate for *in vivo* visualization of carbonic anhydrase IX expression in tumor hypoxia

Anderson H, Pillarsetty N, Cantorias M, Lewis JS\*// \*Memorial Sloan Kettering Canc Ctr, Dept Radiol, Radiochem Serv, New York, NY 10065, USA

*Nucl Med Biol* 2010 **37** (4) 439-442  
Improved synthesis of 2'-deoxy-2-[ $^{18}\text{F}$ ]-fluoro-1- $\beta$ -D-arabinofuranosyl-5-iodouracil ( $^{18}\text{F}$ -FIAU)

Antunes IF, Haisma HJ, Elsinga PH, Dierckx RA, De Vries EFJ// Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, POB 30-001, NL-9700 RB Groningen, The Netherlands

*Bioconjug Chem* 2010 **21** (5) 911-920  
Synthesis and evaluation of [ $^{18}\text{F}$ ]-FEAnGA as a PET tracer for  $\beta$ -glucuronidase activity

Ariza X, Asins G, Garcia J\*, Hegardt FG, Makowski K, Serra D, Velasco J// \*Univ Barcelona, Dept Quim Organ & UBUB, C/ Marti i Franques 1-11, ES-08028 Barcelona, Spain

*J Labelled Comp Radiopharm* 2010 **53** (8) 556-558  
Preparation of  $\alpha$ -labeled aldehydes by base-catalyzed exchange reactions

De Bruyne S, La Regina G, Staelens S, Wyffels L, Deleye S, Silvestri R, De Vos F\*// \*Univ Ghent, Lab Radiopharm, BE-9000 Ghent, Belgium

*Nucl Med Biol* 2010 **37** (4) 459-467  
Radiosynthesis and *in vivo* evaluation of [ $^{11}\text{C}$ ]-labelled pyrrole-2-carboxamide derivatives as novel radioligands for PET imaging of monoamine oxidase A

Debus F, Herth MM, Piel M, Buchholz HG, Bausbacher N, Kramer V, Luddens H, Rosch F// Johannes Gutenberg Univ Mainz, Dept Psychiat, Clin Res Grp, Untere Zahlbacher Str 8, DE-55131 Mainz, Germany

*Nucl Med Biol* 2010 **37** (4) 487-495  
 $^{18}\text{F}$ -labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT $_{2A}$  antagonists for molecular imaging

El-Azony KM// Atomic Energy Authority, Radioactive Isotope & Generators Dept, Hot Lab Ctr, POB 13759, Cairo, Egypt

*J Radioanal Nucl Chem* 2010 **285** (2) 315-320  
Preparation of  $^{125}\text{I}$ -celecoxib with high purity as a possible tumor agent

Gaeta A, Woodcraft J, Plant S, Goggi J, Jones P, Battle M, Trigg W, Luthra SK, Glaser M\*// \*Hammersmith Hosp, GE Healthcare, London W12 0NN, England

*Bioorg Med Chem Lett* 2010 **20** (15) 4649-4652  
Use of 2-[ $^{18}\text{F}$ ]-fluoroethylazide for the Staudinger ligation - Preparation and characterisation of GABA $_A$  receptor binding 4-quinolones

Gomez-Vallejo V, Kato K, Oliden I, Calvo J, Baz Z, Borrell JI, Llop J\*// \*CIC BiomaGUNE, Dept Radiochem, Parque Tecnol San Sebastian, P Miramon 182, ES-20009 San Sebastian, Spain

*Tetrahedron Lett* 2010 **51** (22) 2990-2993  
Fully automated synthesis of  $^{15}\text{N}$ -labeled nitrosothiols

In order to keep subscribers up-to-date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each second issue of the journal. The bibliography contains newly published material in the field of labelled compounds and radiopharmaceuticals. Each bibliography is divided into 16 sections: 1 Radionuclide production; 2 Labelled compound synthesis; Applications: 3 Biomedical - General; 4 Imaging - General; 5 Fluorine; 6 Carbon; 7 Technetium; 8 Iodine; 9 Copper; 10 Gallium; 11 Indium; 12 Hydrogen; 13 Others; 14 Therapy; 15 Environmental; 16 Analytical techniques. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. Unless indicated by an asterisk, the first author is for correspondence.

- He JA, Wang Y, Dou SP, Liu XR, Zhang SR, Liu GZ, Hnatowich D// Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Ctr Mol & Funct Imaging, San Francisco, Ca 94143, USA  
*Mol Pharmacol* 2010 **7** (4) 1118-1124  
Affinity enhancement pretargeting: Synthesis and testing of a  $^{99m}\text{Tc}$ -labeled bivalent MORF
- Hoareau R, Scott PJH// \*Univ Michigan, Dept Radiol, Ann Arbor, MI 48109, USA  
*Tetrahedron Lett* 2010 **51** (26) 3353-3355  
A novel one-pot palladium-mediated synthesis of *N*-[(2-hydroxyphenyl)methyl]-*N*-(4-phenoxy-3-pyridinyl) acetamide, the precursor to [ $^{11}\text{C}$ ]PBR28, a PET biomarker for the peripheral benzodiazepine receptor
- Hocke C, Maschauer S, Hubner H, Lober S, Utz W, Kuwert T, Gmeiner P, Prante O// Univ Erlangen Nurnberg, Clin Nucl Med, Krankenhausstr 12, DE-91054 Erlangen, Germany  
*ChemMedChem* 2010 **5** (6) 941-948  
A series of  $^{18}\text{F}$ -labelled pyridinylphenyl amides as subtype-selective radioligands for the dopamine  $\text{D}_3$  receptor
- Horti AG, Gao YJ, Ravert HT, Finley P, Valentine H, Wong DF, Endres CJ, Savonenko AV, Dannals RF// Johns Hopkins Med Inst, Dept Radiol, Div Nucl Med, 600 Nth Wolfe St, Baltimore, Md 21287, USA  
*Bioorg Med Chem* 2010 **18** (14) 5202-5207  
Synthesis and biodistribution of [ $^{11}\text{C}$ ] A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors ( $\text{CB}_2$ )
- Ibrahim IT, Wally MA// Atomic Energy Authority, Labelled Cpd Dept, Radioisotopes Prod & Radioact Sources Div, Hot Labs Ctr, Cairo, Egypt  
*J Radioanal Nucl Chem* 2010 **285** (2) 169-175  
Synthesis, labeling and biodistribution of  $^{99m}\text{Tc}$ -3-amino-2-quinoxalincarboxitrile 1,4-dioxide in tumor bearing mice
- Kawamura K, Konno F, Yui J, Yamasaki T, Hatori A, Yanamoto K, Wakizaka H, Takei M, Nengaki N, Fukumura T, Zhang MR// Natl Inst Radiol Sci, Dept Mol Probes, Mol Imaging Ctr, 4-9-1 Anagawa, Inage ku, Chiba 263 8555, Japan  
*Ann Nucl Med* 2010 **24** (5) 403-412  
Synthesis and evaluation of [ $^{11}\text{C}$ ]XR9576 to assess the function of drug efflux transporters using PET
- Kim EM, Joung MH, Lee CM, Jeong HJ, Lim ST, Sohn MH, Kim DW// \*Chonbuk Natl Univ, Sch Med, Dept Nucl Med, Jeonju 561 712, Jeonbuk, South Korea  
*Bioorg Med Chem Lett* 2010 **20** (14) 4240-4243  
Synthesis of  $^{99m}\text{Tc}$  labeled 1,2,3-triazole-4-yl *c*-Met binding peptide as a potential *c*-Met receptor kinase positive tumor imaging agent
- Koziorowski J// Univ Copenhagen, Herlev Hosp, Dept Clin Phys Nucl Med, 54P1 Herlev Ringvej 75, DK-2730 Herlev, Denmark  
*Appl Radiat Isot* 2010 **68** (9) 1740-1742  
A simple method for the quality control of [ $^{18}\text{F}$ ]FDG
- Kunstler JU, Seidel G, Pietzsch HJ// \*Forschungszentrum Dresden Rossendorf, Inst Radiopharm, POB 510 119, DE-01314 Dresden, Germany  
*Appl Radiat Isot* 2010 **68** (9) 1728-1733  
Efficient preparation of  $^{99m}\text{Tc}$ (III) '4+1' mixed-ligand complexes for peptide labeling with high specific activity
- Lee JH, Zhou HB, Dence CS, Carlson KE, Welch MJ, Katsenellenbogen JA// \*Univ Illinois, Dept Chem, 600 Sth Mathews Ave, Urbana, Il 61801, USA  
*Bioconjug Chem* 2010 **21** (6) 1096-1104  
Development of [ $^{18}\text{F}$ ]fluorine-substituted tanaproget as a progesterone receptor imaging agent for positron emission tomography
- Li W, Thompson W, Fisher T, Wai JS, Hazuda D, Burns HD, Hamill TG// Merck Res Labs, Imaging Res, WP 44D-2, West Point, Pa 19486, USA  
*J Labelled Comp Radiopharm* 2010 **53** (7) 517-520  
Radiosynthesis of the HIV integrase inhibitor [ $^{18}\text{F}$ ]MK-0518 (Isentress)
- Lin JG, Luo SN\*, Chen CP, Qiu L, Wang Y, Cheng W, Ye WZ, Xia YM// \*Jiangsu Inst Nucl Med, Ministry Hlth Key Lab Nucl Med, CN-214063 Wuxi, Peoples Rep China  
*Appl Radiat Isot* 2010 **68** (9) 1616-1622  
Preparation and preclinical pharmacological study on a novel bone imaging agent  $^{99m}\text{Tc}$ -EMIDP
- Liu GZ, Dou SP, Rusckowski M, Greiner D, Hnatowich D// Univ Massachusetts Sch Med, Div Nucl Med, 55 Lake Ave Nth, Worcester, Ma 01655, USA  
*Appl Radiat Isot* 2010 **68** (9) 1709-1714  
Preparation of  $^{111}\text{In}$ -DTPA morpholino oligomer for low abdominal accumulation
- Liu Y, Oliveira BL, Correia JDG, Santos IC, Santos I, Spingler B, Alberto R// \*Univ Zurich, Inst Inorgan Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland  
*Org Biomol Chem* 2010 **8** (12) 2829-2839  
Synthesis of bifunctional 2,3-diamino propionic acid-based chelators as small and strong tripod ligands for the labelling of biomolecules with  $^{99m}\text{Tc}$
- Lu S, Hong J, Itoh T, Fujita M, Inoue O, Innis RB, Pike VW// Nat Inst Hlth, Nat Inst Mental Hlth, Mol Imaging Branch, 10 Center Dr, Bethesda, Md 20892, USA  
*J Labelled Comp Radiopharm* 2010 **53** (8) 548-551  
[carbonyl- $^{11}\text{C}$ ]Benzyl acetate: Automated radiosynthesis via Pd-mediated [ $^{11}\text{C}$ ]carbon monoxide chemistry and PET measurement of brain uptake in monkey
- Mairinger S, Langer O, Kuntner C, Wanek T, Bankstahl JP, Bankstahl M, Stanek J, Dorner B, Bauer F, Baumgartner C, Loscher W, Erker T\*, Muller M// \*Univ Vienna, Dept Med Chem, Waehringer Guertel 18, AT-1090 Vienna, Austria  
*Nucl Med Biol* 2010 **37** (5) 637-644  
Synthesis and *in vivo* evaluation of the putative breast cancer resistance protein inhibitor [ $^{11}\text{C}$ ] methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate
- Mallia MB, Subramanian S, Mathur A, Sarma HD, Venkatesh M, Banerjee S// \*Bhabha Atomic Res Ctr, Radiopharmaceut Div, IN-400085 Mumbai, India  
*J Labelled Comp Radiopharm* 2010 **53** (8) 535-542  
Synthesis and evaluation of 2-, 4-, 5-substituted nitroimidazole-iminodiacetic acid- $^{99m}\text{Tc}$ (CO) $_3$  complexes to target hypoxic tumors
- Maresca KP, Marquis JC, Hillier SM, Lu GL, Femia FJ, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW// \*Molecular Insight Pharmaceuticals Inc, 150 2 St, Cambridge, Ma 02142, USA  
*Bioconjug Chem* 2010 **21** (6) 1032-1042  
Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: Application to octreotide
- Medine IE, Unak P, Sakarya S, Toksoz F// Ege Univ, Inst Nucl Sci, Dept Nucl Applicat, TR-35100 Izmir, Turkey  
*Cancer Biother Radiopharm* 2010 **25** (3) 335-344  
Enzymatic synthesis of uracil glucuronide, labeling with  $^{125/131}\text{I}$ , and *in vitro* evaluation on adenocarcinoma cells
- Muhlhausen U, Sihver W, Ermert J\*, Coenen HH// \*Forschungszentrum Julich GmbH, Inst Neurosci & Med, INM 5 - Nucl Chem, DE-52425 Julich, Germany  
*Nucl Med Biol* 2010 **37** (5) 605-614  
Synthesis, radiofluorination and first evaluation of [ $^{18}\text{F}$ ]fluorophenylsulfonyl- and [ $^{18}\text{F}$ ]fluorophenylsulfanyl-piperidines as serotonin 5-HT $_{2A}$  receptor antagonists for PET
- Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW// \*NIH/NCI, Radioimmune & Inorgan Chem Sect, Radiat Oncol Branch, 10 Center Dr, Bldg 10, Rm B3B69, Bethesda, Md 20892, USA  
*J Nucl Med* 2010 **51** (6) 942-950  
Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with  $^{86}\text{Y}$  for quantitative PET of carcinoma
- Ogawa M, Nitahara S, Aoki H, Ito S\*, Narazaki M, Matsuda T// \*Kyoto Univ, Grad Sch Engn, Dept Polymer Chem, Nishikyo ku, Kyoto 615 8510, Japan  
*Macromol Chem Phys* 2010 **211** (12) 1369-1376  
Fluorinated polymer nanoparticles as a novel  $^{19}\text{F}$  MRI contrast agent prepared by dendrimer-initiated living radical polymerization
- Pascali G, Mazzone G, Saccomanni G, Manera C, Salvadori PA// Inst Clin Physiol, Radiopharm Dept, Via Moruzzi 1, IT-56124 Pisa, Italy  
*Nucl Med Biol* 2010 **37** (5) 547-555  
Microfluidic approach for fast labeling optimization and dose-on-demand implementation
- Prabhakaran J, Majo VJ, Milak MS, Kassir SA, Palmer M, Savenkova L, Mali P, Arango V, Mann JJ, Parsey RV, Kumar JSD// \*Columbia Univ, Dept Psychiat, Div Mol Imaging & Neuropathol, New York, NY 10032, USA  
*Bioorg Med Chem Lett* 2010 **20** (12) 3499-3501  
Synthesis, *in vitro* and *in vivo* evaluation of [ $^{11}\text{C}$ ]MMTP: A potential PET ligand for mGluR1 receptors
- Prabhakaran J, Majo VJ, Milak MS, Mali P, Savenkova L, Mann JJ, Parsey RV, Kumar JSD// \*Columbia Univ, Dept Psychiat, Div Mol Imaging & Neuropathol, New York, NY 10032, USA  
*Bioorg Med Chem Lett* 2010 **20** (12) 3654-3657  
Synthesis and *in vivo* evaluation of [ $^{11}\text{C}$ ]MPTQ: A potential PET tracer for  $\alpha_2\text{A}$ -adrenergic receptors
- Prenant C, Cawthorne C, Fairclough M, Rothwell N, Boutin H// Univ Manchester, Wolfson Mol Imaging Ctr, Manchester, England  
*Appl Radiat Isot* 2010 **68** (9) 1721-1727  
Radiolabeling with fluorine-18 of a protein, interleukin-1 receptor antagonist
- Rautengarten C, Baidoo E, Keasling JD, Scheller HV// \*Joint Bioenergy Inst, Feedstocks Div, 5885 Hollis St, Emeryville, Ca 94608, USA  
*Bioenergy Res* 2010 **3** (2) 115-122  
A simple method for enzymatic synthesis of unlabeled and radiolabeled hydroxycinnamate-CoA

Shinohara Y, Hasegawa H, Hashimoto T, Ichida K// Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Pathophysiol, 1432-1 Horinouchi, Hachioji, Tokyo 192 0392, Japan

*J Labelled Comp Radiopharm* 2010 **53** (8) 552-555  
 Synthesis of optically active deuterium-labeled homocysteine thiolactone

Simeone JP, Braun MP, Liu L, Natarajan SR// Merck Res Labs, Dept Process Res, PO Box 2000, Rahway, NJ 07065, USA

*J Labelled Comp Radiopharm* 2010 **53** (7) 511-516  
 Palladium-catalyzed hydroxycarbonylation as the key step in the synthesis of a carbon-14 labeled Maxi-K channel blocker

Takada Y, Ogawa M, Suzuki H, Fukumura T\*// \*Nat'l Inst Radiol Sci, Mol Imaging Ctr, Mol Probe Grp, 4-9-1 Anagawa, Inage ku, Chiba 263 8555, Japan

*Appl Radiat Isot* 2010 **68** (9) 1715-1720  
 Radiosynthesis of [2-<sup>14</sup>C-carbonyl]dantrolene using [<sup>14</sup>C]phosgene for PET

Tang G, Tang X, Wang X// First Affiliated Hosp, Sun Yat-Sen Univ, Dept Nucl Med, PET-CT Ctr, CN-510080 Guangzhou, Peoples Rep China

*J Labelled Comp Radiopharm* 2010 **53** (8) 543-547  
 A facile automated synthesis of *N*-succinimidyl 4-[<sup>18</sup>F]fluorobenzoate ([<sup>18</sup>F]SFB) for <sup>18</sup>F-labeled cell-penetrating peptide as PET tracer

Tang GH, Tang XL, Wen FH, Wang MF, Li BY// First Affiliated Hosp, Sun Yat Sen Univ, Dept Nucl Med, PET-CT Ctr, CN-510080 Guangzhou, Guangdong, Peoples Rep China

*Appl Radiat Isot* 2010 **68** (9) 1734-1739  
 A facile and rapid automated synthesis of 3'-deoxy-3'-[<sup>18</sup>F]fluorothymidine

Tu Z, Xu JB, Jones LA, Li SH, Mach RH// Washington Univ Sch Med, Mallinckrodt Inst Radiol, Div Radiol Sci, Campus Box 8225, St Louis, Mo 63110, USA

*Nucl Med Biol* 2010 **37** (4) 509-516  
 Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: Radiosynthesis, *in vitro* and *in vivo* evaluation

Wang LM, Qu WC, Lieberman B, Ploessl K, Kung HF\*// \*Univ Pennsylvania, Dept Radiol, Philadelphia, Pa 19104, USA

*Bioorg Med Chem Lett* 2010 **20** (12) 3482-3485  
 Synthesis and *in vitro* evaluation of <sup>18</sup>F labeled tyrosine derivatives as potential positron emission tomography (PET) imaging agents

Wyffels L, Muccioli GG, Kapanda CN, Labar G, De Bruyne S, De Vos F, Lambert DM\*// \*Catholic Univ Louvain, Louvain Drug Res Inst, Unite Chim Pharmaceut & Radiopharm, UCL-CMFA 73-40, BE-1200 Brussels, Belgium

*Nucl Med Biol* 2010 **37** (5) 665-675  
 PET imaging of fatty acid amide hydrolase in the brain: Synthesis and biological evaluation of an <sup>11</sup>C-labelled URB597 analogue

Yanamoto K, Konno F, Odawara C, Yamasaki T, Kawamura K, Hatori A, Yui J, Wakizaka H, Nengaki N, Takei M, Zhang MR\*// \*Nat'l Inst Radiol Sci, Dept Mol Probes, Mol Imaging Ctr, Inage ku, Chiba 263 8555, Japan

*Nucl Med Biol* 2010 **37** (5) 615-624  
 Radiosynthesis and evaluation of [<sup>14</sup>C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1

Zhang JB, Zhang SJ, Guo HX, Wang XB// Beijing Normal Univ, Coll Chem, MoE Key Lab Radiopharmaceut, CN-100875 Beijing, Peoples Rep China

*Bioorg Med Chem Lett* 2010 **20** (12) 3781-3784  
 Synthesis and biological evaluation of a novel <sup>99m</sup>Tc(CO)<sub>3</sub> complex of ciprofloxacin dithiocarbamate as a potential agent to target infection

## Applications: 3 Biomedical - General

Bergeron DE, Zimmerman BE, Cessna JT// NIST, Phys Lab, 100 Bureau Dr, Stop 8462, Gaithersburg, Md 20899, USA

*Appl Radiat Isot* 2010 **68** (7-8) 1367-1370  
 Development of secondary standards for <sup>223</sup>Ra

Brito GAP, Nunes EA, Nogata C, Yamazaky RK, Naliwaiko K, Curi R, Fernandes LC// Fed Univ Parana, Cell Metab Lab, Polytech Ctr, Jardim Americas, Dept Physiol Biol Sci Bldg, BR-81530-990 Curitiba, Parana, Brazil

*Cell Biochem Funct* 2010 **28** (4) 278-282  
 Lymphocytes transfer [<sup>14</sup>C]-labeled fatty acids to skeletal muscle in culture; modulation by exercise

Caffari Y, Spring P, Bailat C, Nedjadi Y, Bochud F// Inst Radiophys Appl, Grand Pre 1, CH-1007 Lausanne, Switzerland

*Appl Radiat Isot* 2010 **68** (7-8) 1388-1391  
 Activity measurements of <sup>18</sup>F and <sup>90</sup>Y with commercial radionuclide calibrators for nuclear medicine in Switzerland

Dias MS, Silva FFV, Koskinas MF// IPEN CNEN SP, CRPQ, CP 11049, BR-05422-970 Sao Paulo, Brazil

*Appl Radiat Isot* 2010 **68** (7-8) 1349-1353  
 Standardization and measurement of gamma-ray probability per decay of <sup>177</sup>Lu

Felgines C, Krisa S, Mauray A, Besson C, Lamaison JL, Scalbert A, Merillon JM, Texier O// Univ Clermont 1, Lab Pharmacognosie & Phytotherapie, 28 Pl Henri Dunant, BP 38, FR-63001 Clermont Ferrand 1, France

*Br J Nutr* 2010 **103** (12) 1738-1745  
 Radiolabelled cyanidin 3-*O*-glucoside is poorly absorbed in the mouse

Janle EM, Lila MA, Grannan M, Wood L, Higgins A, Yousef GG, Rogers RB, Kim H, Jackson GS, Ho L, Weaver CM// Purdue Univ, Dept Foods & Nutr, 700 West State St, West Lafayette, In 47907, USA

*J Med Food* 2010 **13** (4) 926-933  
 Pharmacokinetics and tissue distribution of <sup>14</sup>C-labeled grape polyphenols in the periphery and the central nervous system following oral administration

Lin YH, Llanos A, Mena P, Uauy R, Salem N, Pawlosky RJ\*// \*Rm 1S-22, 5625 Fishers Lane, Bethesda, Md 20892, USA

*Am J Clin Nutr* 2010 **92** (2) 284-293  
 Compartmental analyses of <sup>2</sup>H<sub>3</sub>- $\alpha$ -linolenic acid and <sup>13</sup>C-U-eicosapentaenoic acid toward synthesis of plasma labeled 22:6n-3 in newborn term infants

Mathews JM, Pulliam D, Black SR, Burka LT// RTI International, Drug Metab & Pharmacokinetics, Cornwallis Rd, Res Triangle Park, NC, USA

*Xenobiotica* 2010 **40** (7) 499-509  
 Metabolism and disposition of [<sup>14</sup>C]dibromoacetone in rats and mice following oral and intravenous administration

Olsovocova V, Iwahara A, Oropesa P, Joseph L, Ravindra A, Ghafoori M, Son HK, Sahagia M, Tastan S, Zimmerman B// Czech Metrol Inst, Radiova 1, CZ-10200 Prague, Czech Republic

*Appl Radiat Isot* 2010 **68** (7-8) 1371-1377  
 National comparison of <sup>131</sup>I measurement among nuclear medicine clinics of eight countries

Sumner SCL, Fennell TR, Snyder RW, Taylor GF, Lewin AH// RTI International, Discovery Sci, Biomarkers & System Biol, 3040 Cornwallis Dr, Research Triangle Park, NC 27709, USA

*J Appl Toxicol* 2010 **30** (4) 354-360  
 Distribution of carbon-14 labeled C60 ([<sup>14</sup>C]C60) in the pregnant and in the lactating dam and the effect of C60 exposure on the biochemical profile of urine

Yamada T, Sato Y, Unno Y, Yunoki A, Hino Y, Ishii K// Japan Radioisotope Association, 2-28-45 Hon-Komagome, Bunkyo ku, Tokyo 113 8941, Japan

*Appl Radiat Isot* 2010 **68** (7-8) 1324-1329  
 Standardization of <sup>99m</sup>Tc and <sup>99</sup>Mo by the use of a 4 $\pi$ B-4 $\pi$  counter

## 4 Imaging - General

Ambrosini V, Tomassetti P, Franchi R, Fanti S\*// \*Azienda Ospedaliero Univ Bologna, Policlin S Orsola Malpighi, Unita Operativa Med Nucl, IT-40138 Bologna, Italy

*Q J Nucl Med Mol Imaging* 2010 **54** (1) 16-23  
 Imaging of NETs with PET radiopharmaceuticals (Review)

Bombardieri E, Coliva A, Maccauro M, Seregini E, Orunesu E, Chiti A, Lucignani G// Ist Nazl Tumori, Via Venezian 1, IT-20133 Milan, Italy

*Q J Nucl Med Mol Imaging* 2010 **54** (1) 3-15  
 Imaging of neuroendocrine tumours with  $\gamma$ -emitting radiopharmaceuticals (Review)

Imam SK// Saad Specialist Hosp, Dept Radiol Nucl Med, Hlth Sci Ctr, POB 30353, SA-31952 Al Khobar, Saudi Arabia

*Cancer Biother Radiopharm* 2010 **25** (3) 365-374  
 Review of positron emission tomography tracers for imaging of tumor hypoxia

Luus C, Hanani R, Reynolds A, Kassiou M\*// \*Univ Sydney, Brain & Mind Res Inst, 100 Mallett St, Camperdown, NSW 2050, Australia

*J Labelled Comp Radiopharm* 2010 **53** (7) 501-510  
 The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned? (Review)

Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG\*// \*UCLA, Dept Mol & Med Pharmacol, 700 Westwood Plaza, Box 951770, Los Angeles, Ca 90024, USA

*J Nucl Med* 2010 **51** (7) 1092-1098  
 Novel PET probes specific for deoxycytidine kinase

Vallabhajosula S, Killeen RP, Osborne JR// Cornell Univ, Weill Cornell Med Coll, Dept Radiol, 525 East 68th St, Starr-221, New York, NY 10065, USA

*Semin Nucl Med* 2010 **40** (4) 220-241  
 Altered biodistribution of radiopharmaceuticals: Role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors (Review)

Wild D, Wicki A, Mansi R, Behe M, Keil B, Bernhardt P, Christofori G, Ell PJ, Macke HR\*// \*Univ Hosp Freiburg, Dept Nucl Med, Hugstetter Str 55, DE-79106 Freiburg, Germany

*J Nucl Med* 2010 **51** (7) 1059-1067  
 Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT

## 5 Fluorine

Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallbohmer D, Prenzel KL, Metzger R, Bollschweiler E, Holscher AH, Monig SP// \*Univ Hosp Cologne, Dept Gen Visceral & Canc Surg, Kerpererstr 62, DE-50937 Cologne, Germany

*Nucl Med Commun* 2010 **31** (6) 532-538

Variable <sup>18</sup>F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression

Apostolova I, Wiemker R, Paulus T, Kabus S, Dreilich T, Van den Hoff J, Plotkin M, Mester J, Brenner W, Buchert R, Klutmann S// Charite Univ Med, Dept Nucl Med, Campus Charite Mitte, Charite Pl 1, DE-13353 Berlin, Germany

*Eur Radiol* 2010 **20** (8) 1868-1877

Combined correction of recovery effect and motion blur for SUV quantification of solitary pulmonary nodules in FDG PET/CT

Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A// Queen Mary Univ London, Barts & London Sch Med, Dept Nucl Med, West Smithfield QE II, London EC1A 7BE, England

*Int J Urol* 2010 **17** (6) 501-511

The clinical advances of fluorine-2-D-deoxyglucose—positron emission tomography/computed tomography in urological cancers (Review)

Bejot R, Kersemans V, Kelly C, Carroll L, King RC, Gouverneur V// \*Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England

*Nucl Med Biol* 2010 **37** (5) 565-575

Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [<sup>18</sup>F]FMISO as hypoxia-selective tracer for PET

Bilici A, Ustaalioglu BBO, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M// Menderes Mah, 364 Sok, Caglar Apt 16, Daire 1, TR-34210 Esener, Turkey

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1259-1269

Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: Is there an impact of FDG PET/CT on patient management?

Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A// \*Rigshospitalet, Dept Clin Physiol Nucl Med & PET, 4011 Blegdamsvej 9, DK-2100 Copenhagen O, Denmark

*Clin Cancer Res* 2010 **16** (3) 978-985

<sup>18</sup>F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors

Bischoff M, Bischoff G\*, Buck A, Von Baer A, Pauls S, Scheffold F, Schultheiss M, Gebhard F, Reske SN// \*Univ Ulm, Dept Thorac & Vasc Surg, Steinhovelstr 9, DE-89075 Ulm, Germany

*Arch Orthop Trauma Surg* 2010 **130** (7) 819-827

Integrated FDG-PET-CT: Its role in the assessment of bone and soft tissue tumors

Blesa J, Juri C, Collantes M, Penuelas I, Prieto E, Iglesias E, Marti-Climent J, Arbizu J, Zubieta JL, Rodriguez-Oroz MC, Garcia-Garcia D, Richter JA, Cavada C, Obeso JA// \*Univ Navarra, Dept Neurol, Clin Univ, Pio XII 35, ES-31008 Pamplona, Spain

*Neurobiol Dis* 2010 **38** (3) 456-463

Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An <sup>18</sup>F-DOPA and <sup>11</sup>C-DTBZ PET study

Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields AF// \*Karmanos Canc Inst, 4100 John R St, HW04HO, Detroit, MI 48201, USA

*Am J Clin Oncol* 2010 **33** (3) 257-261

Using <sup>18</sup>F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer

Cohade C// CHU Montreal, Dept Nucl Med, 3840 St Urbain, Montreal, Quebec, Canada H2W 1T8

*Semin Nucl Med* 2010 **40** (4) 283-293

Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect (Review)

D'Souza MM, Marwaha RK, Sharma R, Jaimini A, Thomas S, Singh D, Jain M, Bhalla PJS, Tripathi M, Tiwari A, Mishra A, Mondal A, Tripathi RP// Inst Nucl Med & Allied Sci, Div PET Imaging, Mol Imaging & Res Ctr, IN-110054 Delhi, India

*Ann Nucl Med* 2010 **24** (5) 345-355

Prospective evaluation of solitary thyroid nodule on <sup>18</sup>F-FDG PET/CT and high-resolution ultrasonography

Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S// Univ Med Ctr Hamburg Eppendorf, Dept Nucl Med, Martinistr 52, DE-20246 Hamburg, Germany

*J Nucl Med* 2010 **51** (6) 862-865

Feasibility of <sup>18</sup>F-sodium fluoride PET/CT for imaging of atherosclerotic plaque

Donati OF, Reiner CS, Hany TF, Fornaro J, Von Schulthess GK, Marincek B, Weishaupt D// Univ Zurich Hosp, Inst Diagn Radiol, Ramistr 100, CH-8091 Zurich, Switzerland

*Nuklearmedizin* 2010 **49** (3) 106-114

<sup>18</sup>F-FDG-PET and MRI in patients with malignancies of the liver and pancreas accuracy of retrospective multimodality image registration by using the CT-component of PET/CT

Farrag A, Ceulemans G, Voordeckers M, Everaert H, Storme G// Assiut Univ Hosp, Dept Clin Oncol, Assiut, Egypt

*Nucl Med Commun* 2010 **31** (6) 495-501

Can <sup>18</sup>F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients?

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, Schadmand-Fischer S, Bartenstein P, Lackner KJ, Kloppel G, Schreckenberger M, Weber MM// Johannes Gutenberg Univ Mainz, Med Clin 1, Dept Endocrinol & Metab, Langenbeckstr 1, DE-55131 Mainz, Germany

*J Clin Endocrinol Metab* 2010 **95** (6) 2800-2810

<sup>6</sup>-<sup>18</sup>F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to <sup>123</sup>I-metaiodobenzyl-guanidine scintigraphy in the detection of extra-adrenal and hereditary pheochromocytomas and paragangliomas: Correlation with vesicular monoamine transporter expression

Gravius S, Gebhard M, Ackermann D, Bull U, Hermanns-Sachweh B, Mumme T// Univ Bonn, Klin & Poliklin Orthopädie & Unfallchirurg, Siegmund Freud Str 25, DE-53127 Bonn, Germany

*Nuklearmedizin* 2010 **49** (3) 115-123

Analysis of <sup>18</sup>F-FDG uptake pattern in PET for diagnosis of aseptic loosening versus prosthesis infection after total knee arthroplasty: A prospective pilot study (German, English Abstract)

Groshar D, Bernstine H, Stern D, Sosna J, Eligalashvili M, Gurbuz EG, Niv Y, Fraser G// Rabin Med Ctr, Dept Nucl Med, Jabotinsky St, IL-49100 Petah Tiqva, Israel

*J Nucl Med* 2010 **51** (7) 1009-1014

PET/CT enterography in Crohn disease: Correlation of disease activity on CT enterography with <sup>18</sup>F-FDG uptake

Gulyas B, Brockschneider D, Nag S, Pavlova E, Kasa P, Beliczai Z, Legradi A, Gulya K, Thiele A, Dyrks T, Halldin C// Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, SE-17176 Stockholm, Sweden

*Neurosci Int* 2010 **56** (6-7) 789-798

The norepinephrine transporter (NET) radioligand (*S,S*)-[<sup>18</sup>F]FMeNER-D<sub>2</sub> shows significant decreases in NET density in the human brain in Alzheimer's disease: A post-mortem autoradiographic study

Haeusler D, Nics L, Mien LK, Ungersbroeck J, Lanzemberger RR, Shanab K, Sindelar KM, Vierstein H, Wagner KH, Dudczak R, Kletter K, Wadsak W, Mitterhauser M// \*Med Univ Vienna, Dept Nucl Med, Waehringer Guertel 18-20, AT-1090 Vienna, Austria

*Nucl Med Biol* 2010 **37** (4) 421-426

[<sup>18</sup>F]FE@SUPPY and [<sup>18</sup>F]FE@SUPPY:2—metabolic considerations

Ho L, Valenzuela D, Negahban A, Wassef H// Univ Sthn Calif, Keck Sch Med, Dept Radiol, Div Nucl Med, PET Imaging Sci Ctr, Los Angeles, CA 90033, USA

*Clin Nucl Med* 2010 **35** (7) 487-489

Primary spinal epidural non-Hodgkin lymphoma demonstrated by FDG PET/CT

Hossain AKMM, Shulkin BL\*, Gelfand MJ, Bashir H, Daw NC, Sharp SE, Nadel HR, Dome JS// \*St Jude Childrens Hosp, Dept Radiol Sci, Nucl Imaging Div, MS 220, 262 Danny Thomas Pl, Memphis, TN 38105, USA

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1300-1308

FDG positron emission tomography/computed tomography studies of Wilms' tumor

Hu H, Su L, Xu YQ, Zhang H, Wang LW// \*Fudan Univ, Huashan Hosp, Sch Med, Dept Psychiat, 12 Wulumuqi Rd - Middle, CN-200040 Shanghai, Peoples Rep China

*Neuroscience* 2010 **169** (1) 171-181

Behavioral and [<sup>18</sup>F] fluorodeoxyglucose micro positron emission tomography imaging study in a rat chronic mild stress model of depression

Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H// Saitama Med Univ, Dept Nucl Med, Int Med Ctr, 1397-1 Yamane, Hidaka City, Saitama, Japan

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1318-1327

<sup>18</sup>F-FDG versus <sup>11</sup>C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: The time period during which PET/CT can reliably detect non-recurrence

Jansen I, Hendriksz TR, Han SH, Huiskes AWLC, Van Bommel EFH// \*Albert Schweitzer Hosp, Dept Internal Med, POB 444, NL-3300 AK Dordrecht, The Netherlands

*Eur J Intern Med* 2010 **21** (3) 216-221

<sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis

- Janssen MHM, Ollers MC, Riedl RG, Van den Bogaard J, Buijsen J, Van Stiphout RGPM, Aerts HJWL, Lambin P, Lammering G// Maastricht Clin, Dr Tanslaan 12, Box 3035, NL-6202 NA Maastricht, The Netherlands  
*Int J Radiat Oncol Biol Phys* 2010 **77** (2) 392-399  
 Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging
- Kaida H, Ishibashi M, Yuzuriha M, Kurata S, Arikawa S, Kawahara A, Uozumi J, Uchida M, Kobayashi M, Hirose Y, Fujita H, Kage M, Hayabuchi N// Kurume Univ, Div Nucl Med, 67 Asahi machi, Fukuoka 830 0011, Japan  
*Clin Nucl Med* 2010 **35** (7) 505-509  
 Glucose transporter expression of an esophageal gastrointestinal tumor detected by <sup>18</sup>F FDG PET/CT
- Kim DW, Jung SA, Kim CG, Park SA// \*Wonkwang Univ, Sch Med, Dept Nucl Med, 344-2 Shinyong dong, Iksan 570 711, Jeollabuk do, South Korea  
*Clin Nucl Med* 2010 **35** (6) 400-403  
 The efficacy of dual time point <sup>18</sup>F FDG PET imaging for grading of brain tumors
- Kim IJ, Kim SS, Kim SJ\*, Lee CH, Kim YK// \*Pusan Natl Univ, Sch Med, Dept Nucl Med, 1-10 Ami dong, Seo gu, Pusan 602 739, South Korea  
*Cancer Biother Radiopharm* 2010 **25** (3) 309-315  
 Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer
- Kim WH, Kim SH\*, Kim YH, Youn SH, Kang WJ, Kim MA, Han JK, Choi BI// \*Seoul Natl Univ Hosp, Dept Radiol, 28 Yeongon dong, Chongno gu, Seoul 110 744, South Korea  
*Abdom Imaging* 2010 **35** (4) 437-446  
 Fluorine-18-FDG PET findings of focal eosinophilic liver disease: Correlation with CT and/or MRI, laboratory, and pathologic findings
- Kim YK, Lee KW\*, Cho SY, Han SS, Kim SH, Kim SK, Park SJ// \*Natl Canc Ctr, Ctr Liver Canc, 323 Ilsan ro, Goyang si 410 769, Gyeonggi do, South Korea  
*Liver Transplant* 2010 **16** (6) 767-772  
 Usefulness <sup>18</sup>F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients
- Kley K, Oehr P\*// \*Am Buechel 53a, DE-53173 Bonn, Germany  
*Anticancer Res* 2010 **30** (5) 1741-1745  
 Usefulness of combined FDG-PET with CT or tumour markers in lung cancer diagnosis
- Kyoto Y, Momose M\*, Kondo C, Itabashi M, Kameoka S, Kusakabe K// \*Tokyo Womens Med Univ, Dept Diagn Imaging & Nucl Med, 8-1 Kawada cho, Shinjuku ku, Tokyo 162 8666, Japan  
*Ann Nucl Med* 2010 **24** (5) 395-401  
 Ability of <sup>18</sup>F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations
- Law MP, Wagner S, Kopka K, Renner C, Pike VW, Schober O, Schafers M// Univ Hosp Munster, Dept Nucl Med, DE-48149 Munster, Germany  
*Nucl Med Biol* 2010 **37** (4) 517-526  
 Preclinical evaluation of an <sup>18</sup>F-labelled  $\beta_1$ -adrenoceptor selective radioligand based on ICI 89,406
- Lee JH, Park SG, Jee KN, Park DG, Namgung H, Song IH// Dankook Univ, Coll Med, Dept Nucl Med, Cheonan 330 715, South Korea  
*Nucl Med Commun* 2010 **31** (6) 576-582  
 Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level
- Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH, Yen TC\*, Kung MP// \*Chang Gung Memorial Hosp, Dept Nucl Med, Kaohsiung, Taiwan  
*Nucl Med Biol* 2010 **37** (4) 497-508  
 Whole-body biodistribution and brain PET imaging with [<sup>18</sup>F]AV-45, a novel amyloid imaging agent - A pilot study
- Liu YY, Ghesani NV, Zuckier LS// Univ Hosp, Nucl Med Sect, 150 Bergen St, H-141, Newark, NJ 07103, USA  
*Semin Nucl Med* 2010 **40** (4) 294-315  
 Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy (Review)
- Matthews R, Shrestha P, Franceschi D, Relan N, Kaloudis E// Hlth Sci Ctr, Dept Radiol, Stony Brook, NY 11794, USA  
*Clin Nucl Med* 2010 **35** (7) 494-498  
 Head and neck cancers post-therapy changes in muscles with FDG PET-CT
- Menda Y, Ponto LLB, Dornfeld KJ, Tewson TJ, Watkins GL, Gupta AK, Anderson C, McGuire S, Schultz MK, Sunderland JJ, Graham MM, Buatti JM// Univ Iowa, Univ Iowa Hosp & Clin, Roy J & Lucille A Carver Coll Med, Dept Radiol, Div Nucl Med, Iowa City, Ia 52242, USA  
*Nucl Med Biol* 2010 **37** (4) 433-438  
 Investigation of the pharmacokinetics of 3'-deoxy-3'-[<sup>18</sup>F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer
- Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, Groves AM// UCL Hosp, Inst Nucl Med, 235 Euston Rd, London NW1 2BU, England  
*Atherosclerosis* 2010 **211** (1) 136-140  
 What is the natural history of <sup>18</sup>F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque
- Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, De Leon MJ// NYU Sch Med, Dept Psychiat, 560 First Ave, New York, NY 10016, USA  
*J Alzheimers Dis* 2010 **20** (3) 843-854  
 Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging (Review)
- Nowak AK, Francis RJ, Phillips MJ, Millward MJ, Van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ// Sir Charles Gairdner Hospital, Sch Med & Pharmacol, 4th Floor, G Block, Hospital Ave, Perth, WA 6009, Australia  
*Clin Cancer Res* 2010 **16** (8) 2409-2417  
 A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters
- Okubo M, Nishimura Y\*, Nakamatsu K, Okumura M, Shibata T, Kanamori S, Hanaoka K, Hosono M// \*Kinki Univ, Sch Med, Dept Radiat Oncol, 377-2 Ohno Higashi, Osaka 589 8511, Japan  
*Int J Radiat Oncol Biol Phys* 2010 **77** (2) 350-356  
 Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancers: A multiple-threshold method for [<sup>18</sup>F]fluoro-2-deoxyglucose activity
- Ozulker T, Kucukoz A, Ozulker F, Ozpacaci T// Okmeydani Training & Res Hosp, Darusafaka mh Gazeteciler sitesi C3 D9 Maslak, Istanbul, Turkey  
*Nucl Med Commun* 2010 **31** (6) 597-603  
 Comparison of <sup>18</sup>F-FDG-PET/CT with <sup>99m</sup>Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients
- Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, Ansquer C, Testard A, Resche I, Bridji B, Kraeber-Bodere F, Rousseau C\*// \*Rene Gauducheau Canc Ctr, Dept Nucl Med, St Herblain, France  
*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1270-1278  
 Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma
- Pfannenbergs C, Aschoff P, Dittmann H, Mayer F, Reischl G, Von Wayhern C, Kanz L, Clausen CD, Bares R, Hartmann JT// Univ Tubingen, Dept Radiol & Nucl Med, Hoppe Seyler Str 3, DE-72076 Tubingen, Germany  
*J Nucl Med* 2010 **51** (6) 845-853  
 PET/CT with <sup>18</sup>F-FLT: Does it improve the therapeutic management of metastatic germ cell tumors?
- Picchio M, Mangili G, Samanes Gajate AM, De Marzi P, Spinapoliche EG, Mapelli P, Giovacchini G, Sigismondi C, Vignano R, Sironi S, Messa C// Ist Sci San Raffaele, Dept Nucl Med, Via Olgettina 60, IT-20132 Milan, Italy  
*Nucl Med Commun* 2010 **31** (6) 506-512  
 High-grade endometrial cancer: Value of [<sup>18</sup>F]FDG PET/CT in preoperative staging
- Ponto LLB, Menda Y, Dornfeld K, Tewson TJ, Watkins GL, Sunderland J, Graham MM, Buatti J// Univ Iowa Hosp & Clin, Dept Radiol, PET Imaging Ctr, 09112 JPP, 200 Hawkins Dr, Iowa City, Ia 52242, USA  
*Cancer Biother Radiopharm* 2010 **25** (3) 361-363  
 Stability of 3'-deoxy-3'-[<sup>18</sup>F]fluorothymidine standardized uptake values in head and neck cancer over time
- Rabkin Z, Israel O, Keidar Z\*// \*Rambam Hlth Care Campus, Dept Nucl Med, IL-35254 Haifa, Israel  
*J Nucl Med* 2010 **51** (7) 1015-1020  
 Do hyperglycemia and diabetes affect the incidence of false-negative <sup>18</sup>F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis
- Raczka KA, Becker G, Seese A, Frisch S, Heiner S, Marschhauser A, Barthel H, Scheid R, Sabri O, Schroeter ML\*// \*Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1a, DE-04103 Leipzig, Germany  
*Psychiatr Res Neuroimaging* 2010 **182** (3) 274-280  
 Executive and behavioral deficits share common neural substrates in fronto-temporal lobar degeneration - A pilot FDG-PET study
- Rominger A, Mille E, Boning G, Wangler B, Gildehaus FJ, Arszol C, Bartenstein P, Cumming P// Univ Munich, Dept Nucl Med, Marchioninstr 15, DE-81377 Munich, Germany  
*Synapse* 2010 **64** (8) 654-657  
 $\alpha_2$ -Adrenergic drugs modulate the binding of [<sup>18</sup>F]fallypride to dopamine D<sub>2/3</sub> receptors in striatum of living mouse
- Rommel D, Abarca-Quinones J, Bol A, Peeters F, Lhommel R, Lonnew M, Labar D, Gregoire V, Duprez T// Catholic Univ Louvain, Clin Univ St Luc CLIN 2942, Dept Radiol & Med Imaging, BE-1200 Brussels, Belgium  
*Nucl Med Biol* 2010 **37** (5) 645-653  
 Early monitoring of external radiation therapy by [<sup>18</sup>F]-fluoromethylcholine positron emission tomography and 3-T proton magnetic resonance spectroscopy: An experimental study in a rodent rhabdomyosarcoma model

- Rudd JHF, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, Tahara N, Fuster V, Warburton EA, Fayad ZA, Tawakol AA// Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, ACCE, Box 110, Hills Rd, Cambridge CB2 2QQ, England  
*J Am Coll Cardiol* 2010 **55** (23) 2527-2535  
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography (Review)
- Ryu SY, Kim K, Kim Y, Park SI, Kim BJ, Kim MH, Choi SC, Lee ED, Lee KH, Kim BI// Korea Canc Ctr Hosp, Dept Obstet & Gynecol, KIRAMS, 75 Nowon gil, Nowon gu, Seoul 139 706, South Korea  
*J Korean Med Sci* 2010 **25** (7) 1029-1033  
Detection of recurrence by <sup>18</sup>F-FDG PET in patients with endometrial cancer showing no evidence of disease
- Saba W, Valette H\*, Granon S, Xiao YX, Kellar KJ, Dolle F, Bottlaender M// \*CEA, Serv Hosp Frederic Joliot, I2BM, FR-91401 Orsay, France  
*Synapse* 2010 **64** (7) 570-572  
[<sup>18</sup>F]ZW-104, a new radioligand for imaging  $\alpha$ 2- $\alpha$ 3- $\alpha$ 4/ $\beta$ 2 central nicotinic acetylcholine receptors: Evaluation in mutant mice
- Sekine M, Arakawa R, Ito H\*, Okumura M, Sasaki T, Takahasji H, Takano H, Okubo Y, Halldin C, Suhara T// \*Natl Inst Radiol Sci, Mol Neuroimaging Grp, Mol Imaging Ctr, 4-9-1 Anagawa, Inage ku, Chiba 263 8555, Japan  
*Psychopharmacology (Berl)* 2010 **210** (3) 331-336  
Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[<sup>18</sup>F]FMcNER-D<sub>2</sub>
- Shamim SA, Kumar R\*, Halanaik D, Shandal V, Reddy RM, Bal CS, Malhotra A// \*E-81 Ansari Nagar E, AIIMS Campus, IN-110029 New Delhi, India  
*Nucl Med Commun* 2010 **31** (6) 590-596  
Role of FDG-PET/CT in detection of recurrent disease in colorectal cancer
- Shim SS, Han J// Ewha Womans Univ, Mokdong Hosp, Sch Med, Ewha Med Res Inst, Dept Radiol, Ctr Imaging Sci, Ewha Med Ctr, Seoul 158 710, South Korea  
*Ann Nucl Med* 2010 **24** (5) 357-362  
FDG-PET/CT imaging in assessing mucin-producing non-small cell lung cancer with pathologic correlation
- Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB// Gachon Univ Med & Sci, Neurosci Res Inst, 1197 Kuwol dong, Namdong gu, Incheon 405 760, South Korea  
*Neuroimage* 2010 **52** (2) 488-496  
Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG
- Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, Tolis G, Datsis IE// Evangelismos Med Ctr, Dept Nucl Med, 45-47 Ipsilandou St, GR-10676 Athens, Greece  
*Nucl Med Commun* 2010 **31** (6) 567-575  
Role of [<sup>18</sup>F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer
- Takenaka D, Ohno Y\*, Koyama H, Nogami M, Onishi Y, Matsumoto K, Matsumoto S, Yoshikawa T, Sugimura K// \*Kobe Univ, Grad Sch Med, Dept Radiol, 7-5-2 Kusunoki cho, Chuo ku, Kobe, Hyogo 650 0017, Japan  
*Eur J Radiol* 2010 **74** (3) 458-464  
Integrated FDG-PET/CT vs. standard radiological examinations: Comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients
- Tanimoto K, Yoshikawa K, Obata T, Ikehira H, Shiraiishi T, Watanabe K, Saga T, Mizoe J, Kamada T, Kato A, Miyazaki M// 4-9-1 Anagawa, Inage ku, Chiba, Japan  
*Nucl Med Commun* 2010 **31** (6) 604-609  
Role of glucose metabolism and cellularity for tumor malignancy evaluation using FDG-PET/CT and MRI
- Testemassi E, Kubota K\*, Morooka M, Ito K, Masuda-Miyata Y, Yamashita H, Ito K, Mimori A, Kuroki H// \*Natl Ctr Global Hlth & Med, Dept Radiol, Div Nucl Med, 1-21-1 Toyama, Shinjuku ku, Tokyo 162 8655, Japan  
*Ann Nucl Med* 2010 **24** (5) 421-425  
Constrictive tuberculous pericarditis diagnosed using <sup>18</sup>F-fluorodeoxyglucose positron emission tomography: A report of two cases
- Troost EGC, Bussink J, Hoffmann AL, Boerman OC, Oyen WJG, Kaanders JHAM// Radboud Univ Nijmegen Med Ctr, Inst Oncol, Dept Radiat Oncol, POB 9101, NL-6500 HB Nijmegen, The Netherlands  
*J Nucl Med* 2010 **51** (6) 866-874  
<sup>18</sup>F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors
- Vriens D, Visser EP, De Geus-Oei LF, Oyen WJG// Radboud Univ Nijmegen Med Ctr, Dept Nucl Med, Internal Postal Code 444, NL-6500 HB Nijmegen, The Netherlands  
*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1408-1425  
Methodological considerations in quantification of oncological FDG PET studies (Review)
- Wang JL, Oya S, Parhi AK, Lieberman BP, Ploessi K, Hou C, Kung HF// \*University Pennsylvania Sch Med, Dept Radiol, Philadelphia, Pa 19104, USA  
*Nucl Med Biol* 2010 **37** (4) 479-486  
*In vivo* studies of the SERT-selective [<sup>18</sup>F]FPBM and VMAT2-selective [<sup>18</sup>F]AV-133 radiotracers in a rat model of Parkinson's disease
- Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasic JR, Ye WG, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ// Johns Hopkins Univ Sch Med, Johns Hopkins Med Inst, Solomon H Snyder Dept Neurosci, Baltimore, Md 21287, USA  
*J Nucl Med* 2010 **51** (6) 913-920  
*In vivo* imaging of amyloid deposition in Alzheimer disease using the radioligand <sup>18</sup>F-AV-45 (Flobetapir F 18)
- Yang WF, Zhang YM, Fu Z, Yu JM\*, Sun XR, Mu DB, Han AQ// \*Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jiyan Rd 440, CN-250117 Jinan, Shandong, Peoples Rep China  
*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1291-1299  
Imaging of proliferation with <sup>18</sup>F-FLT PET/CT versus <sup>18</sup>F-FDG PET/CT in non-small-cell lung cancer
- Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, Hong RL, Yu CJ, Wang KL, Yang RS// \*7 Chung Shan Sth Rd, Taipei 100, Taiwan  
*Nucl Med Commun* 2010 **31** (7) 637-645  
The diagnostic and prognostic effectiveness of <sup>18</sup>F sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients
- Yilmaz M, Adli M, Celen Z, Zincirkeser S, Dirier A// Gaziantep Univ, Sch Med, Dept Nucl Med, TR-27310 Gaziantep, Turkey  
*Nucl Med Commun* 2010 **31** (6) 526-531  
FDG PET-CT in cervical cancer: Relationship between primary tumor FDG uptake and metastatic potential
- Yun M, Noh TW\*, Cho A, Choi YJ, Hong SW, Park CS, Lee JD, Kim CK// \*Yonsei Univ, Coll Med, Dept Internal Med, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, South Korea  
*J Clin Endocrinol Metab* 2010 **95** (7) 3182-3188  
Visually discernible [<sup>18</sup>F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: A potential new risk factor

## 6 Carbon

- Ashworth S, Rabiner EA, Gunn RN, Plisson C, Wilson AA, Comley RA, Lai RYK, Gee AD, Laruelle M, Cunningham VJ// Imperial Coll London, GlaxoSmithKline Clin Imaging Ctr, Hammersmith Hosp, London W12 0NN, England  
*J Nucl Med* 2010 **51** (7) 1021-1029  
Evaluation of <sup>11</sup>C-GSK189254 as a novel radioligand for the H<sub>3</sub> receptor in humans using PET
- Boecker H, Weindl A, Brooks DJ, Ceballos-Baumann AO, Liedtke C, Miederer M, Sprenger T, Wagner KJ, Miederer I// Univ Bonn, Radiol Univ Klin, FE Klin Funkt Neurobildgebung, Sigmund Freud Str 25, DE-53127 Bonn, Germany  
*J Nucl Med* 2010 **51** (7) 1030-1035  
GABAergic dysfunction in essential tremor: An <sup>11</sup>C-flumazenil PET study
- Dandois V, Rommel D, Renard L, Jamart J, Cosnard G// Catholic Univ Louvain, Dept Med Imaging, MRI Unit, Clin Univ St Luc, 10 Ave Hippocrate, BE-1200 Brussels, Belgium  
*J Neuroradiol* 2010 **37** (2) 89-97  
Substitution of <sup>11</sup>C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: Preliminary results in clinical practice
- Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C, Farde L// Karolinska Univ, Karolinska Univ Hosp, Dept Clin Neurosci, Psychiat Sect, SE-17176 Stockholm, Sweden  
*Synapse* 2010 **64** (7) 573-577  
Fenfluramine-induced serotonin release decreases [<sup>11</sup>C]AZ10419369 binding to 5-HT<sub>1B</sub>-receptors in the primate brain
- Jarkas N, Voll RJ, Williams L, Goodman MM// \*Emory Ctr System Imaging, NE Dept Radiol, Wesley Woods Hlth Ctr, Atlanta, Ga 30329, USA  
*Nucl Med Biol* 2010 **37** (5) 593-603  
Validation of two fluoro-analogues of *N,N*-dimethyl-2-(2'-amino-4'-hydroxymethyl-phenylthio)benzylamine as serotonin transporter imaging agents using microPET
- Kawamura K, Naganawa M, Konno F, Yui J, Wakizaka H, Yamasaki T, Yanamoto K, Hatori A, Takei M, Yoshida Y, Sakaguchi K, Fukumura T, Kimura Y, Zhang MR// Natl Inst Radiol Sci, Dept Mol Probes, Mol Imaging Ctr, Chiba 263 8555, Japan  
*Nucl Med Biol* 2010 **37** (5) 625-635  
Imaging of I<sub>2</sub>-imidazoline receptors by small-animal PET using 2-(3-fluoro-[4-<sup>11</sup>C]tolyl)-4,5-dihydro-1*H*-imidazole ([<sup>11</sup>C]FTIMD)

Kikuchi A, Takeda A\*, Okamura N, Tashiro M, Hasegawa T, Furumoto S, Kobayashi M, Sugeno N, Baba T, Miki Y, Mori F, Wakabayashi K, Funaki Y, Iwata R, Takahashi S, Fukuda H, Arai H, Kudo Y, Yanai K, Itoyama Y// \*Tohoku Univ, Grad Sch Med, Dept Neurol, 1-1 Seiryomachi, Aoba ku, Sendai, Miyagi 980 8574, Japan  
*Brain* 2010 **133** (6) 1772-1778

*In vivo* visualization of  $\alpha$ -synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy

Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I// Univ Toronto, Human Neurochem Pathol Lab, Ctr Addiction & Mental Hlth, 250 College St, Toronto, Ontario, Canada M5T 1R8  
*Brain* 2010 **133** (6) 1779-1797

Decreased cerebral cortical serotonin transporter binding in Ecstasy users: A positron emission tomography/[<sup>11</sup>C]DASB and structural brain imaging study

Liu RS, Chang CP, Guo WY, Pan DHC, Ho DMT, Chang CW, Yang BH, Wu LC, Yeh SH// Natl Yang Ming Univ Sch Med, Dept Nucl Med, 201 Sec 2 Shih Pai Rd, Taipei 112, Taiwan  
*J Nucl Med* 2010 **51** (6) 883-891

1-<sup>11</sup>C-acetate versus <sup>18</sup>F-FDG PET in detection of meningioma and monitoring the  $\gamma$ -effect of knife radiosurgery

Passchier J, Gentile G, Porter R, Herdon H, Salinas C, Jakobsen S, Audrain H, Laruelle M, Gunn RN// Univ London, Imperial Coll Sci Technol & Med, Hammersmith Hosp, Clin Imaging Ctr, GlaxoSmithKline, London W12 0NN, England  
*Synapse* 2010 **64** (7) 542-549

Identification and evaluation of [<sup>11</sup>C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography

Wijnen JP, Van der Graaf M, Scheenen TWJ, Klomp DWJ, De Galan BE, Idema AJS, Heerschap A// Radboud Univ Nijmegen Med Ctr, Dept Radiol, POB 9101, NL-6500 HB Nijmegen, The Netherlands  
*Magn Reson Imaging* 2010 **28** (5) 690-697

*In vivo* <sup>13</sup>C magnetic resonance spectroscopy of a human brain tumor after application of <sup>13</sup>C-1-enriched glucose

Winter A, Uphoff J, Henke RP, Wawroschek F// Hosp Oldenburg, Dept Urol & Paediat Urol, Rahel Straus Str 10, DE-26133 Oldenburg, Germany  
*Urol Int* 2010 **84** (4) 418-423

First results of [<sup>11</sup>C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy

Yokoyama C, Yamanaka H, Onoe K, Kawasaki A, Nagata H, Shirakami K, Doi H, Onoe H// \*RIKEN Ctr Mol Imaging Sci, Funct Probe Res Lab, 6-7-3 Minatojima, Chuo ku, Kobe, Hyogo 650 0047, Japan  
*Synapse* 2010 **64** (8) 594-601

Mapping of serotonin transporters by positron emission tomography with [<sup>11</sup>C]DASB in conscious common marmosets: Comparison with rhesus monkeys

## 7 Technetium

Bahk YW, Jeon HS, Kim JM, Park JM, Chung YA\*, Kim EE, Kim SH, Chung SK// \*Catholic Univ Korea, Incheon St Marys Hosp, Dept Radiol, 665 Bupyeong dong, Bupyeong gu, Incheon, South Korea  
*Skeletal Radiol* 2010 **39** (8) 807-813

Novel use of gamma correction for precise <sup>99m</sup>Tc-HDP pinhole bone scan diagnosis and classification of knee occult fractures

Bolzati C, Cavazza-Ceccato M, Agostini S, Refosco F, Yamamichi Y, Tokunaga S, Carta D, Salvarese N, Bernardini D, Bandoli G// ICIS-CNR, Corso Stati Uniti 4, IT-35127 Padua, Italy  
*Bioconjug Chem* 2010 **21** (5) 928-939

Biological *in vitro* and *in vivo* studies of a series of new asymmetrical cationic [<sup>99m</sup>Tc(N)(DTC-Ln)(PNP)]<sup>+</sup> complex (DTC-Ln = alicyclic dithiocarbamate and PNP = disphosphinoamine)

Franken PR, Guglielmi J, Vanhove C, Koulibaly M, Defrise M, Darcourt J, Pourcher T\*// \*Faculty Med, TIRO, 28 Ave Valombrose, FR-06107 Nice, France  
*Thyroid* 2010 **20** (5) 519-526

Distribution and dynamics of <sup>99m</sup>Tc-pertechnetate uptake in the thyroid and other organs assessed by single-photon emission computed tomography in living mice

Gorenberg M, Radan L, Kosakov R, Amirav I// Technion - Israel Inst Technol, Rappaport Fac Med, Dept Nucl Med, Bnai Zion Med Ctr, IL-13100 Haifa, Israel  
*Nucl Med Commun* 2010 **31** (7) 682-685

The Bnai Zion Planar Method: A simplified technique for the quantitation of the absolute renal uptake of <sup>99m</sup>Tc-DMSA in children

Kang L, Wang RF\*, Yan P, Liu M, Zhang CL, Yu MM, Cui YG, Xu XJ// \*Peking Univ First Hosp, Dept Nucl Med, 8 Xishiku St, CN-100034 Beijing, Peoples Rep China  
*J Nucl Med* 2010 **51** (6) 978-986

Noninvasive visualization of RNA delivery with <sup>99m</sup>Tc-radiolabeled small-interference RNA in tumor xenografts

Kim S, Kim HK\*, Kang DY, Jeong JM, Choi YH// \*97 Guro dongkil, Guro ku, Seoul 152 703, South Korea  
*Eur J Cardiothorac Surg* 2010 **37** (6) 1450-1456

Quantitative comparison of yttrium-90 (<sup>90</sup>Y)-microspheres and technetium-99m (<sup>99m</sup>Tc)-macroaggregated albumin SPECT images for planning <sup>90</sup>Y therapy of liver cancer

Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang ZY, Heiba S// Mt Sinai Med Ctr, Div Nucl Med, Box 1141, 1 Gustave L Levy Pl, New York, NY 10029, USA  
*Technol Cancer Res Treat* 2010 **9** (3) 253-262

Intra-operative sentinel lymph node identification using a novel receptor-binding agent (technetium-99m neomannosyl human serum albumin, <sup>99m</sup>Tc-MSA) in stage I non-small cell lung cancer

Kudoh H, Fujiwara S\*, Shiotani H, Kawai H, Hirata K// \*Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, 7-5-1 Kusunoki cho, Chuo ku, Kobe, Hyogo 650 0017, Japan  
*Ann Nucl Med* 2010 **24** (5) 379-385

Myocardial washout of <sup>99m</sup>Tc-tetrofosmin and response to steroid therapy in patients with cardiac sarcoidosis

Pavlovic S, Artiko V, Sobic-Saranovic D, Damjanovic S, Popovic B, Jakovic R, Petrasinovic Z, Jaksic E, Todorovic-Tirmanic M, Saranovic DJ, Micev M, Novosel S, Nikolic N, Obradovic V// Institute Nuclear Medicine, Belgrade, Serbia  
*Neoplasma* 2010 **57** (1) 68-73

The utility of <sup>99m</sup>Tc-EDDA/HYNIC-TOC scintigraphy for assessment of lung lesions in patients with neuroendocrine tumors

Ponto JA// Univ Iowa Hosp & Clin, Div Nucl Med, 200 Hawkins Dr, Iowa City, Ia 52242, USA  
*J Am Pharm Assoc* 2010 **50** (3) 419-423

Radiopharmaceutical considerations for using <sup>99m</sup>Tc MAA in lung transplant patients

Seok JW, Choi YS, Chong S, Kwon GY, Chung YJ, Kim BG, Park SJ// Chung Ang Univ, Coll Med, Dept Nucl Med, 224-1 Heukseok dong, Dongjak gu, Seoul 156 755, South Korea  
*Breast Cancer Res Treat* 2010 **122** (2) 453-457

Sentinel lymph node identification with radiopharmaceuticals in patients with breast cancer: A comparison of <sup>99m</sup>Tc-tin colloid and <sup>99m</sup>Tc-phytate efficiency

Swanson TW, Chan SK, Jones SJ, Bugis S, Irvine R, Belzberg A, Levine D, Wiseman SM\*// \*St Pauls Hosp, Dept Surg, Vancouver, Brit Columbia, Canada V6Z 1Y6  
*Am J Surg* 2010 **199** (5) 614-620

Determinants of <sup>99m</sup>Tc sestamibi SPECT scan sensitivity in primary hyperparathyroidism

Zeintl J, Vija AH, Yahil A, Homegger J, Kuwert T// Univ Erlangen Nurnberg, Clin Nucl Med, Pattern Recognition Lab, Krankenhausstr 12, DE-91054 Erlangen, Germany  
*J Nucl Med* 2010 **51** (6) 921-928

Quantitative accuracy of clinical <sup>99m</sup>Tc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction

## 8 Iodine

Akizawa H, Zhao SJ, Takahashi M, Nishijima K, Kuge Y, Tamaki N, Seki K, Ohkura K\*// \*Hlth Sci Univ Hokkaido, Fac Pharmaceut Sci, Ishikari, Hokkaido 061 029, Japan  
*Nucl Med Biol* 2010 **37** (4) 427-432

*In vitro* and *in vivo* evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging

Avcibasi U, Demiroglu H, Unak P, Muftuler FZB, Ichedef CA, Gumuser FG// Celal Bayar University, Fac Art & Sci, Dept Chem, TR-45030 Manisa, Turkey  
*J Radioanal Nucl Chem* 2010 **285** (2) 207-214

*In vivo* biodistribution of <sup>131</sup>I labeled bleomycin (BLM) and isomers (A2 and B2) on experimental animal models

Cosgrove KP, Staley JK, Baldwin RM, Bois F, Plisson C, Al-Tikriti MS, Seibyl JP, Goodman MM, Tamagnan GD// Yale Univ Sch Med, VA Connecticut HCS 116A6, West Haven, Ct 06516, USA  
*Nucl Med Biol* 2010 **37** (5) 587-591

SPECT imaging with the serotonin transporter radiotracer [<sup>123</sup>I]p ZIENT in nonhuman primate brain

- De Bruyne S, Wyffels L, Boos TL, Staelens S, Deleye S, Rice KC, De Vos F\*// \*Univ Ghent, Lab Radiopharm, BE-9000 Ghent, Belgium  
*Nucl Med Biol* 2010 **37** (4) 469-477  
*In vivo* evaluation of [<sup>123</sup>I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine, an iodinated SPECT tracer for imaging the P-gp transporter
- Fletcher AM, Motherwell DW, Small AD, McCurrach GM, Goodfield NER, Petrie MC, Martin W, Cobbe SM// Queens Med Res Inst, Clin Res Imaging Ctr, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland  
*Nucl Med Commun* 2010 **31** (7) 629-636  
<sup>123</sup>I MIBG cardiac uptake measurements: Limitations of collimator choice and scatter correction in the clinical context
- Jacobson AF, Deng HW, Lombard J, Lessig HJ, Black RR// GE Healthcare, 101 Carnegie Ctr, Princeton, NJ 08540, USA  
*J Clin Endocrinol Metab* 2010 **95** (6) 2596-2606  
<sup>123</sup>I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: Results of a meta-analysis (Review)
- Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunderson TH, Sagona J, Rigopoulos A, Smyth FE, Johns TG, Govindan SV, Goldenberg DM, Old LJ, Scott AM\*// \*Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia  
*J Nucl Med* 2010 **51** (6) 967-972  
Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using <sup>124</sup>I-IMP-R4-labeled antibody ch806
- Nakanishi R, Fujimoto S\*, Utanohara Y, Takamura K, Inoue A, Yamashina S, Namiki A, Yamazaki J// \*Toho Univ, Dept Cardiovasc Med, Omori Med Ctr, 6-11-1 Omori nishi, Ohta ku, Tokyo 143 8541, Japan  
*Nucl Med Commun* 2010 **31** (6) 488-494  
Significance of performing <sup>123</sup>I-metaiodobenzylguanidine myocardial scintigraphy at different times for the long-term prediction of cardiac events in patients with dilated cardiomyopathy
- Taki J, Inaki A, Wakabayashi H, Imanaka-Yoshida K, Ogawa K, Hiroe M, Shiba K, Yoshida T, Kinuya S// Kanazawa Univ Hosp, Dept Nucl Med, 13-1 Takara machi, Kanazawa, Ishikawa 920 864, Japan  
*J Nucl Med* 2010 **51** (7) 1116-1122  
Dynamic expression of tenascin-C after myocardial ischemia and reperfusion: Assessment by <sup>125</sup>I-anti-tenascin-C antibody imaging
- Tomiguchi S, Tashiro K, Shiraishi S, Yoshida M, Kawanaka K, Takahashi Y, Soma T, Yamashita Y// Kumamoto Univ, Dept Diagn Radiol, Japan  
*Ann Nucl Med* 2010 **24** (5) 387-393  
Estimation of <sup>123</sup>I-IMP arterial blood activity from dynamic planar imaging of the chest using a graph plot method for the quantification of regional cerebral blood flow
- Van der Veen L, Scholte A, Stokkel M\*// \*Leiden Univ Med Ctr, Dept Cardiol, Div Nucl Med, POB 9600, NL-2300 RC Leiden, The Netherlands  
*Nucl Med Commun* 2010 **31** (7) 617-628  
Mathematical methods to determine quantitative parameters of myocardial <sup>123</sup>I-MIBG studies: A review of the literature
- Wang JL, Deutsch EC, Oya S, Kung HF\*// \*Univ Pennsylvania Sch Med, Dept Radiol, Philadelphia, Pa 19104, USA  
*Nucl Med Biol* 2010 **37** (5) 577-586  
FlipADAM: A potential new SPECT imaging agent for the serotonin transporter
- ## 9 Copper
- Li L, Turatti F, Crow D, Bading JR, Anderson AL, Poku E, Yazaki PJ, Williams LE, Tamvakis D, Sanders P, Leong D, Raubitschek A, Hudson PJ, Colcher D, Shively JE\*// \*Beckman Res Inst, Dept Immunol, City of Hope Natl Med Ctr, 1450 East Duarte Rd, Duarte, Ca 91010, USA  
*J Nucl Med* 2010 **51** (7) 1139-1146  
Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney and high tumor-to-blood ratios resulting in improved <sup>64</sup>Cu PET
- Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Morita T, Yoshii H, Oh M, Asai T, Okazawa H, Welch MJ, Fujibayashi Y\*// \*Univ Fukui, Biomed Imaging Res Ctr, Fukui 910 1193, Japan  
*Nucl Med Biol* 2010 **37** (4) 395-404  
Copper-64-diacetyl-bis (N-4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma
- ## 10 Gallium
- Banerjee SR, Pullambhatia M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG\*// \*Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Orleans St, Baltimore, Md 21231, USA  
*J Med Chem* 2010 **53** (14) 5333-5341  
<sup>68</sup>Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer
- Brom M, Oyen WJG, Joosten L, Gotthardt M, Boerman OC// Radboud Univ Nijmegen Med Ctr, Dept Nucl Med, POB 9101, NL-6500 HB Nijmegen, The Netherlands  
*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1345-1355  
<sup>68</sup>Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET
- Eder M, Knackmuss S, Le Gall F, Reusch U, Rybin V, Little M, Haberkorn U, Mier W, Eisenhut M// German Canc Res Ctr, Im Neuenheimer Feld 280, DE-69120 Heidelberg, Germany  
*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1397-1407  
<sup>68</sup>Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours
- Eder M, Krivoshein AV, Backer M, Backer JM, Haberkorn U, Eisenhut M// German Canc Res Ctr, DE-69120 Heidelberg, Germany  
*Nucl Med Biol* 2010 **37** (4) 405-412  
scVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: Comparison of easy-to-label recombinant proteins for [<sup>68</sup>Ga]PET imaging of VEGF receptors in angiogenic vasculature
- Kratochwil C, Giesel FL, Lopez-Benitez R, Schimpfky N, Kunze K, Eisenhut M, Kauczor HU, Haberkorn U// Univ Heidelberg Hosp, Dept Nucl Med, INF 400, DE-69120 Heidelberg, Germany  
*Clin Cancer Res* 2010 **16** (10) 2899-2905  
Intraindividual comparison of selective arterial versus venous <sup>68</sup>Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors
- Love C, Palestro CJ// St Vincent Catholic Med Ctr, Div Nucl Med, 170 West 12th St, New York, NY 10011, USA  
*Semin Nucl Med* 2010 **40** (4) 271-282  
Altered biodistribution and incidental findings on gallium and labeled leukocyte/bone marrow scans (Review)
- Middendorp M, Selinski I, Happel C, Kranert WT, Grunwald F// Univ Frankfurt Klinikum, Klin Nucl Med, Theodor Stern Kai 7, DE-60590 Frankfurt, Germany  
*Q J Nucl Med Mol Imaging* 2010 **54** (1) 76-83  
Comparison of positron emission tomography with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]DOTATOC in recurrent differentiated thyroid cancer: Preliminary data
- Prasad V, Baum RP\*// \*Zentralklinik Bad Berka, Dept Nucl Med/Ctr PET, Robert Koch Allee 9, DE-99437 Bad Berka, Germany  
*Q J Nucl Med Mol Imaging* 2010 **54** (1) 61-67  
Biodistribution of the <sup>68</sup>Ga labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: Characterization of uptake in normal organs and tumor lesions
- Prinsen K, Li JJ, Vanbilloen H, Vermaelen P, Devos E, Mortelmans L, Bormans G, Ni YC, Verbruggen A// KUL, Fac Pharmaceut Sci, Lab Radiopharm, Herestr 49, Box 821, BE-3000 Louvain, Belgium  
*Bioorg Med Chem* 2010 **18** (14) 5274-5281  
Development and evaluation of a <sup>68</sup>Ga labeled pamoic acid derivative for *in vivo* visualization of necrosis using positron emission tomography
- Putzer D, Gabriel M, Kandler D, Henninger B, Knoflach M, Kroiss A, Vongugenberg E, Warwitz B, Virgolini I// Innsbruck Med Univ, Dept Nucl Med, Anichstr 35, AT-6020 Innsbruck, Austria  
*Q J Nucl Med Mol Imaging* 2010 **54** (1) 68-75  
Comparison of <sup>68</sup>Ga-DOTA-Tyr<sup>3</sup>-octreotide and <sup>18</sup>F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients
- Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, Chang CH, Laverman P, Disselhorst JA, Eek A, Van der Graaf WT, Oyen WJ, Boerman OC// Radboud Univ Nijmegen Med Ctr, Dept Nucl Med, POB 9101, NL-6500 HB Nijmegen, The Netherlands  
*Mol Cancer Ther* 2010 **9** (4) 1019-1027  
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a <sup>68</sup>Ga and <sup>18</sup>F-labeled haptens peptide in mice with human tumor xenografts
- Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J\*// \*UCL Hosp, Inst Nucl Med, 235 Euston Rd, London NW1 2BU, England  
*J Nucl Med* 2010 **51** (6) 875-882  
The role of <sup>68</sup>Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on <sup>111</sup>In-DTPA-octreotide scintigraphy
- Tolmachev V, Velikyan I, Sandstrom M, Orlova A// Uppsala Univ, Div Biomed Radiat Sci, Rudbeck Lab, SE-75181 Uppsala, Sweden  
*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1356-1367  
A HER2-binding affibody molecule labelled with <sup>68</sup>Ga for PET imaging: Direct *in vivo* comparison with the <sup>111</sup>In-labelled analogue
- Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kandler D, Eisterer W, Bale R, Putzer D, Gabriel M, Virgolini I\*// \*Med Univ Innsbruck, Dept Nucl Med, Anichstr 35, AT-6020 Innsbruck, Austria  
*Q J Nucl Med Mol Imaging* 2010 **54** (1) 52-60  
Preliminary experience with <sup>68</sup>Ga-DOTA-lanreotide positron emission tomography



## II Indium

Ahlgren S, Orlova A, Wallberg H, Hansson M, Sandstrom M, Lewsley R, Wennborg A, Abrahmsen L, Tolmachev V\*, Feldwisch J// \*Uppsala Univ, Dept Radiol Oncol & Clin Immunol, Div Biomed Radiat Sci, Rudbeck Lab, SE-75185 Uppsala, Sweden

*J Nucl Med* 2010 **51** (7) 1131-1138

Targeting of HER2-expressing tumors using <sup>111</sup>In-ABY-025, a second-generation Affibody molecule with a fundamentally reengineered scaffold

Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J// \*Affibody AB, Lindhagensgatan 133, SE-11251 Stockholm, Sweden

*J Nucl Med* 2010 **51** (6) 892-897

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic <sup>111</sup>In or <sup>68</sup>Ga-labeled Affibody molecules

Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A// \*Ist Clin Humanitas, Milan, Italy

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1441-1448

<sup>111</sup>In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging

Cascini GL, Cuccurullo V\*, Mansi L// \*Univ Naples 2, Div Nucl Med, Piazza Miraglia 2, IT-80138 Naples, Italy

*Q J Nucl Med Mol Imaging* 2010 **54** (1) 24-36

The non tumour uptake of <sup>111</sup>In-octreotide creates new clinical indications in benign diseases but also in oncology (Review)

Chakraborty S, Shi JY, Kim YS, Zhou Y, Jia B, Wang F, Liu S// \*Purdue University, Sch Hlth Sci, 550 Stadium Mall Dr, West Lafayette, IN 47907, USA

*Bioconjug Chem* 2010 **21** (5) 969-978

Evaluation of <sup>111</sup>In-labeled cyclic RGD peptides: Tetrameric not tetravalent

Melis M, Vejt E, Konijnenberg MW, De Visser M, Bijster M, Vermeij M, Krenning EP, Boerman OC, De Jong M// Erasmus MC, Dept Nucl Med, S Gravendijkwal 230, NL-3015 CE Rotterdam, The Netherlands

*J Nucl Med* 2010 **51** (6) 973-977

Nephrotoxicity in mice after repeated imaging using <sup>111</sup>In-labeled peptides

Mussig K, Oksuz MO, Dudziak K, Ueberberg B, Wehrmann M, Horger M, Schulz S, Haring HU, Pfannenbergs C, Bares R, Gallwitz B, Petersenn S// Univ Klinikum Tubingen, Med Klin IV, Otfried Muller Str 10, DE-72076 Tubingen, Germany

*Horm Metab Res* 2010 **42** (8) 599-606

Association of somatostatin receptor 2 immunohistochemical expression with [<sup>111</sup>In]-DTPA octreotide scintigraphy and [<sup>68</sup>Ga]-DOTATOC PET/CT in neuroendocrine tumors

Nayak TK, Dennis MK, Ramesh C, Burai R, Atcher RW, Sklar LA, Norenberg JP, Hathaway HJ, Arterburn JB, Prossnitz ER// \*University New Mexico Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131, USA

*ACS Chem Biol* 2010 **5** (7) 681-690

Influence of charge on cell permeability and tumor imaging of GPR30-targeted <sup>111</sup>In-labeled nonsteroidal imaging agents

Schroeder RPI, Muller C, Reneman S, Melis ML, Breeman WAP, De Blois E, Bangma CH, Krenning EP, Van Weerden WM, De Jong M// Erasmus MC, Dept Expt Urol, Dr Molewaterplei 50, NL-3015 GE Rotterdam, The Netherlands

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1386-1396

A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues

## II2 Hydrogen

Peng T, Zysk J, Dorff P, Elmore CS, Strom P, Malmquist J, Ding M, Tuke D, Werkheiser J, Widzowski D, Mrzljak L, Maier D// AstraZeneca, CNS Discovery, Department Neuroscience, 1800 Concord Pike, Wilmington, DE 19850, USA

*Synapse* 2010 **64** (8) 624-633

D<sub>2</sub> receptor occupancy in conscious rat brain is not significantly distinguished with [<sup>3</sup>H]-MNPDA, [<sup>3</sup>H]-(+)-PNHO, and [<sup>3</sup>H]-raclopride

## II3 Others

Backus BE, Hezemans REL, Verburg FA, Keijsers RGM, Konijnenberg MW, Verzijlbergen JF// St Antonius Hosp, Dept Nucl Med, Koekoekslaan 1, Postbus 2500, NL-3430 EM Nieuwegein, The Netherlands

*Nucl Med Commun* 2010 **31** (6) 539-546

Effect of time and exercise on the clearance rate of <sup>201</sup>Ti in normal and ischemic myocardium

Bravo PE, Chien D, Javadi M, Merrill J, Bengel FM// \*Johns Hopkins Univ Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Div Nucl Med, Baltimore, Md 21287, USA

*J Nucl Med* 2010 **51** (6) 898-905

Reference ranges for LVEF and LV volumes from electrocardiographically gated <sup>82</sup>Rb cardiac PET/CT using commercially available software

Hoeban BAW, Kaanders JHAM, Franssen GM, Troost EGC, Rijken PFJW, Oosterwijk E, Van Dongen GAMS, Oyen WJG, Boerman OC, Bussink J// Radboud Univ Nijmegen Med Ctr, Dept Radiat Oncol, POB 9101, NL-6500 HB Nijmegen, The Netherlands

*J Nucl Med* 2010 **51** (7) 1076-1083

PET of hypoxia with <sup>89</sup>Zr-labeled cG250-F(ab)<sub>2</sub> in head and neck tumors

Nayak TK, Regino CAS, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW// \*NIH/NCI, 10 Center Dr, MSC 1002, Bldg 10, Rm B3B69, Bethesda, Md 20892, USA

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1368-1376

PET imaging of HER1-expressing xenografts in mice with <sup>86</sup>Y-CHX-A"-DTPA-cetuximab

## II4 Therapy

Akinlolu O, Ottolino-Perry K, McCart JA, Reilly RM// \*Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, 144 College St, Toronto, Ontario, Canada M5S 3M2

*Cancer Biother Radiopharm* 2010 **25** (3) 325-333

Antiproliferative effects of <sup>111</sup>In- or <sup>177</sup>Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor

Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, Kronauge JF, Boyd M, Mairs RJ, Babich JW// Molecular Insight Pharmaceuticals Inc, Dept Res & Dev, 160 2nd St, Cambridge, Ma 01450, USA

*Cancer Biother Radiopharm* 2010 **25** (3) 299-308

Comparison of high-specific-activity ultratrace <sup>123</sup>I/<sup>131</sup>I-MIBG and carrier-added <sup>123</sup>I/<sup>131</sup>I-MIBG on efficacy, pharmacokinetics, and tissue distribution

Bodei L, Pepe G, Paganelli G// \*European Inst Oncol, Div Nucl Med, Milan, Italy

*Eur Rev Med Pharmacol Sci* 2010 **14** (4) 347-351

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues (Review)

Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, Orunesu E, Luksch R, Bombardieri E// Natl Canc Inst, Div Nucl Med, Via Venezian 1, IT-20133 Milan, Italy

*Q J Nucl Med Mol Imaging* 2010 **54** (1) 100-113

<sup>131</sup>I-MIBG treatment of pheochromocytoma: Low versus intermediate activity regimens of therapy

Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Muller-Brand J, Macke H, Reubi JC, Merio A// Univ Basel Hosp, Div Neurosurg, CH-4031 Basel, Switzerland

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1335-1344

Targeted  $\alpha$ -radionuclide therapy of functionally critically located gliomas with <sup>213</sup>Bi-DOTA-[Thi<sup>8</sup>,Met(O<sub>2</sub>)<sup>11</sup>]-substance P: A pilot trial

Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM// \*Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, 144 College St, Toronto, Ontario, Canada M5S 3M2

*J Nucl Med* 2010 **51** (7) 1084-1091

Antitumor effects and normal-tissue toxicity of <sup>111</sup>In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts

Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, Rossi A, Bartolomei M, Mei R, Severi S, Salvatori M, Pedroli G, Paganelli G// \*European Institute Oncol, Div Nucl Med, Via Ripamonti 435, IT-20141 Milan, Italy

*Q J Nucl Med Mol Imaging* 2010 **54** (1) 37-51

Dosimetry for treatment with radiolabelled somatostatin analogues. A review

Dannoon SF, Bigott-Hennkens HM, Ma LX, Gallazzi F, Lewis MR, Jurisson SS// \*Univ Missouri, Dept Chem, Columbia, Mo 65211, USA

*Nucl Med Biol* 2010 **37** (5) 527-537

In vitro structure-activity relationship of re-cyclized octreotide analogues

Das T, Chakraborty S, Sarma HD, Banerjee S, Venakatesh M// Bhabha Atom Res Ctr, Radiopharmaceut Div, IN-400085 Mumbai, India

*Nucl Med Biol* 2010 **37** (5) 655-663

A novel <sup>177</sup>Lu-labeled porphyrin for possible use in targeted tumor therapy

DeNardo G, DeNardo S// 1508 Alhambra Blvd, Rm 3100, Sacramento, Ca 95816, USA

*Semin Nucl Med* 2010 **40** (2) 136-144

Dose intensified molecular targeted radiotherapy for cancer-lymphoma as a paradigm (Review)

Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, Koral KF, Kaminski MS, Avram AM// Univ Michigan, Dept Radiol, Div Nucl Med, 1301 Catherine, 2276 Med Sci I/5610, Ann Arbor, MI 48109, USA

*J Nucl Med* 2010 **51** (7) 1155-1162

<sup>131</sup>I tositumab radioimmunotherapy: Initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling

Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, Kendler D, Virgolini IJ// Innsbruck Med Univ, Dept Nucl Med, Anichstr 35, AT-6020 Innsbruck, Austria

*Q J Nucl Med Mol Imaging* 2010 **54** (1) 92-99

Individualized peptide-related-radiionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients

Gan F, Chen LX, Liu XW, Shiu YT, Zhang WG, Fan W\*// \*Sun Yat Sen University, Department Nuclear Medicine, Cancer Centre, 651 Dongfeng Road East, CN-510060 Guangzhou, Guangdong Province, Peoples Rep China

*Cancer Biother Radiopharm* 2010 **25** (3) 345-352

A pilot study on the feasibility of real-time calculation of three-dimensional dose distribution for <sup>153</sup>Sm-EDTMP radionuclide therapy based on the voxel S-values

Goldsmith SJ// New York Presbyterian Hospital, Weill Cornell College Medicine, Div Nucl Med, Weill Cornell Med Ctr, New York, NY 10065, USA

*Semin Nucl Med* 2010 **40** (2) 122-135

Radioimmunotherapy of lymphoma: Bexxar and Zevalin (Review)

Grunwald F, Ezziddin S// Univ Hosp Frankfurt, Dept Nucl Med, Theodor Stern Kai 7, DE-60590 Frankfurt, Germany

*Semin Nucl Med* 2010 **40** (2) 153-163

<sup>131</sup>I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors (Review)

Joyal JL, Barrett JA, Marquis JC, Chen JQ, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, Pomper MG, Babich JW\*// \*Molecular Insight Pharmaceuticals, 160 Second Street, Cambridge, Massachusetts 02142, USA

*Cancer Res* 2010 **70** (10) 4045-4053

Preclinical evaluation of an <sup>131</sup>I-labeled benzamide for targeted radiotherapy of metastatic melanoma

Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C\*// \*Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, 388-1 Pungnap 2 dong, Songpa gu, Seoul 138 736, South Korea

*Invest New Drugs* 2010 **28** (4) 516-522

Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

Kletting P, Meyer C, Reske SN, Glatting G\*// \*Univ Ulm, Klin Nucl Med, Albert Einstein Allee 23, DE-89081 Ulm, Germany

*Cancer Biother Radiopharm* 2010 **25** (3) 279-287

Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: An investigation based on pharmacokinetic modeling

Krajewski S, Bilewicz A// Inst Nucl Chem & Technol, ul Dorodna 16, PL-03195 Warsaw, Poland

*J Radioanal Nucl Chem* 2010 **285** (2) 293-300

The stability of the <sup>105</sup>[Rh(16S<sub>4</sub>dio)Cl<sub>2</sub>]<sup>+</sup> radiopharmaceutical precursor in solutions containing human plasma thiols

Kwekkeboom DJ, De Herder WW, Van Eijck CHJ, Kam BL, Van Essen M, Teunissen JJM, Krenning EP// Erasmus University Medical Centre, Department Nuclear Medicine, Dr Molewaterplein 40, NL-3015 Rotterdam, The Netherlands

*Semin Nucl Med* 2010 **40** (2) 78-88

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors (Review)

Paes FM, Serafini AN\*// \*University Miami, Department Radiol, Div Nucl Med, Jackson Memorial Med Ctr, 1611 NW 12th Ave, Miami, FL 33136, USA

*Semin Nucl Med* 2010 **40** (2) 89-104

Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain (Review)

Riaz A, Kulik LM, Mulcahy MF, Lewandowski RJ, Salem R\*// \*Northwestern University, Department Radiology, Division Interventional Oncology, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA

*Semin Oncol* 2010 **37** (2) 94-101

Yttrium-90 radioembolization in the management of liver malignancies (Review)

Seregini E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Boggi A, Bombardieri E// Natl Canc Inst, IT-20133 Milan, Italy

*Q J Nucl Med Mol Imaging* 2010 **54** (1) 84-91

Treatment with tandem [<sup>90</sup>Y]DOTA-TATE an [<sup>177</sup>Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: Preliminary results

Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H// Univ Hosp Cologne, Dept Nucl Med, Kerpener Str 62, DE-50937 Cologne, Germany

*Eur J Nucl Med Mol Imaging* 2010 **37** (7) 1279-1290

Dosimetry for <sup>131</sup>I-MIBG therapies in metastatic neuroblastoma, pheochromocytoma and paraganglioma

Sward C, Bernhardt P, Ahlman H, Wangberg B, Forssell-Aronsson E, Larsson M, Svensson J, Rossi-Norrlund R, Kolby L// University Gothenburg, Sahlgrenska University Hospital, Department Surg, SE-41345 Gothenburg, Sweden

*World J Surg* 2010 **34** (6) 1368-1372

[<sup>177</sup>Lu-DOTA<sup>0</sup>-Tyr<sup>3</sup>]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: The value of measuring absorbed dose to the kidney

Tzanopoulou S, Sagnou M, Paravatou-Petsotas M, Gourmi E, Loudos G, Xanthopoulos S, Lefkas D, Kiaris H, Varvarigou A, Pirmettis IC, Papadopoulos M, Pelecanou M\*// \*Natl Ctr Sci Res Demokritos, Inst Biol, GR-15310 Athens, Greece

*J Med Chem* 2010 **53** (12) 4633-4641

Evaluation of Re and <sup>99m</sup>Tc complexes of 2-(4'-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals

Vegt E, De Jong M, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, Gotthardt M, Boerman OC// Maastricht Univ Med Ctr, GROW - Sch Oncol & Dev Biol, Dept Nucl Med, POB 5800, NL-6202 AZ Maastricht, The Netherlands

*J Nucl Med* 2010 **51** (7) 1049-1058

Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy and strategies for prevention (Overview)

Zhao JH, Qiao WL, Zhang YN, Shao XX// First Peoples Hosp, Shanghai Jiao Tong Univ, Dept Nucl Med, 85 Wujin Rd, CN-200080 Shanghai, Peoples Rep China

*Cancer Biother Radiopharm* 2010 **25** (3) 353-359

Preparation and *in vitro* evaluation of <sup>131</sup>I-BmK CT as a glioma-targeted agent

## 15 Environmental

Martinazzo R, Jablonowski ND, Hamacher G, Dick DP, Burauel P// Univ Fed Rio Grande do Sul, Dept Soil Sci, Ave Bento Gonçalves 7712, BR-91540-000 Porto Alegre, RS, Brazil

*J Agric Food Chem* 2010 **58** (13) 7864-7870

Accelerated degradation of <sup>14</sup>C-atrazine in Brazilian soils from different regions

Snyder EH, O'Connor GA, McAvoy DC// University Alaska, Department Health Science, DPL 404, 3211 Providence Drive, Anchorage, AK 99508, USA

*Sci Total Environ* 2010 **408** (13) 2726-2732

Fate of <sup>14</sup>C-triclocharban in biosolids-amended soils

## 16 Analytical techniques

Athersuch TJ, Castro-Perez J, Rodgers C, Nicholson JK, Wilson ID\*// \*AstraZeneca, Drug Metab & Pharmacokinetics, Dept Clin Pharmacol, Alderley Pk, Macclesfield SK10 4TG, England

*Xenobiotica* 2010 **40** (7) 510-523

UPLC-MS, HPLC-radiometric, and NMR-spectroscopic studies on the metabolic fate of 3-fluoro-[U-<sup>14</sup>C]-aniline in the bile-cannulated rat

Jiang W, Wysocki VH, Dodds ED, Miesfeld RL, Scaraffia PY\*// \*University Arizona, Department Chemistry & Biochemistry, Tucson, Arizona 85721, USA

*Anal Biochem* 2010 **404** (1) 40-44

Differentiation and quantification of C1 and C2 <sup>13</sup>C-labeled glucose by tandem mass spectrometry

Mousseau G, Raffy Q, Thomas OP, Agez M, Thai R, Renault JP, Pin S, Ochsenein F, Cintrat JC\*, Rousseau B// \*Commissariat Energie Atomique, Institut Biologie & Technologies de Saclay, FR-91191 Gif-sur-Yvette, France

*Biochemistry* 2010 **49** (20) 4297-4299

Footprinting of protein interactions by tritium labeling